Trust the Process: Prolonged Babesia Parasitemia in an Elderly Man with Asplenia from the American Midwest.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
18 Jul 2022
18 Jul 2022
Historique:
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
BACKGROUND Babesia species are intraerythrocytic parasitic protozoa that are endemic to the Northeast and north Midwest of the United States. Babesia microti is the most common cause of babesiosis in North America and causes a malaria-like tick-borne parasitosis. Babesia is commonly transmitted through the bite of Ixodes species ticks, often concomitantly with other tick-borne organisms such as Borrelia burgdorferi, Ehrlichia, Rickettsia rickettsii, and Anaplasma phagocytophilum. In the Midwest, Lyme disease is the most common tick-borne illness, and other organisms can sometimes be overlooked. The risk of tick-borne parasitic or bacterial infection is increased in patients after splenectomy. CASE REPORT An 89-year-old man with asplenia and multiple other comorbidities presented to the Emergency Department after a fall at home preceded by 2 to 3 days of fever and loss of appetite and 1 week of generalized weakness. The patient had thrombocytopenia, leukocytosis with neutrophilia, transaminitis, hyperbilirubinemia, and elevated creatine kinase level consistent with tick-borne illness. Laboratory testing revealed Borrelia and Babesia co-infection and other culprits were ruled out via high sensitivity PCR. Owing to the patient's asplenic status, the babesiosis was slow to resolve with appropriate treatment. After an extended 8-week treatment with azithromycin and atovaquone, the patient demonstrated clinical resolution of babesiosis with a negative blood smear. CONCLUSIONS First-line treatment with azithromycin and atovaquone is effective in treating babesiosis even in complicated patients, such as this elderly, asplenic patient. However, in cases such as this, an extended course of a first-line treatment regimen is still appropriate.
Identifiants
pubmed: 35844076
pii: 936326
doi: 10.12659/AJCR.936326
pmc: PMC9305988
doi:
Substances chimiques
Azithromycin
83905-01-5
Atovaquone
Y883P1Z2LT
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e936326Références
Am J Med. 1984 Apr;76(4):696-701
pubmed: 6424470
Clin Infect Dis. 2006 Nov 1;43(9):1089-134
pubmed: 17029130
Infect Immun. 2015 Jan;83(1):8-16
pubmed: 25312951
Front Microbiol. 2018 Jan 31;9:85
pubmed: 29445365
JAMA. 2016 Apr 26;315(16):1767-77
pubmed: 27115378
Infect Dis Clin North Am. 2008 Sep;22(3):469-88, viii-ix
pubmed: 18755385
Pathogens. 2019 Jul 17;8(3):
pubmed: 31319461
Clin Infect Dis. 2008 Feb 1;46(3):370-6
pubmed: 18181735
PLoS One. 2012;7(10):e46553
pubmed: 23071588
Front Microbiol. 2019 Jul 10;10:1596
pubmed: 31354683